Eli Lilly (LLY) Q4 FY24 earnings call

Eli Lilly delivered a strong Q4 FY24, driven by robust growth in its incretin franchise, Mounjaro and Zepbound, which also led to significant revenue and EPS beats for the full year. The company is aggressively expanding manufacturing capacity and advancing a broad pipeline, including multiple Phase III programs for Orforglipron and Retatrutide. While facing some pricing headwinds and Trulicity declines, Lilly remains highly bullish on the long-term potential of the obesity market and its pipeline, balancing investment in R&D with sustainable growth.